**Name of journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 46010**

**Manuscript type: REVIEW**

**Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma**

Lee SM *et al*. FDG PET in HCC

Sang Mi Lee, Hong Soo Kim, Sangheun Lee, Jeong Won Lee

**Sang Mi Lee,** Department of Nuclear Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Chungcheongnam-do 31151, South Korea

**Hong Soo Kim,** Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, Chungcheongnam-do 31151, South Korea

**Sangheun Lee,** Division of Hepatology, Department of Internal medicine, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, Incheon 22711, South Korea

**Sangheun Lee,** Institute for Health and Life Science, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, Incheon 22711, South Korea

**Jeong Won Lee,** Department of Nuclear Medicine, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, Incheon 22711, South Korea

**ORCID number:** Sang Mi Lee (0000-0002-7943-3807); Hong Soo Kim (0000-0003-3966-9302); Sangheun Lee (0000-0002-7884-1622); Jeong Won Lee (0000-0002-2697-3578).

**Author contributions**: All authors equally contributed to this paper with conception and design of the study, literature review, drafting, revision, editing of the paper, and approval of the final version.

**Supported by** the Soonchunhyang University Research Fund.

**Conflict-of-interest statement:** No potential conflicts of interest.

**Open-Access:** This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author: Jeong Won Lee, MD, PhD, Associate Professor,** Department of Nuclear Medicine, Catholic Kwandong University College of Medicine, International St. Mary’s Hospital, 25, Simgok-ro 100 beon-gil, Seo-gu, Incheon 22711, South Korea. jwlee223@ish.ac.kr

**Telephone:** +82-32-2902975

**Fax:** +82-32-2903128

**Received:** January 24, 2019

**Peer-review started:** January 24, 2019

**First decision:** February 21, 2019

**Revised:** February 25, 2019

**Accepted:** March 1, 2019

**Article in press:**

**Published online:**

**Abstract**

Hepatocellular carcinoma (HCC) is one of major causes of cancer mortality worldwide. For decades, 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been wide used for staging, predicting prognosis, and detecting cancer recurrence in various types of malignant diseases. Due to low sensitivity of FDG PET for detecting intrahepatic HCC lesions, the clinical value of FDG PET in HCC patients has been limited. However, recent studies with diverse analytic methods have shown that FDG PET has promising role in aiding management of HCC patients. In this review, we will discuss the clinical role of FDG PET for staging, predicting prognosis, and evaluating treatment response in HCC. Further, we will focus on recent clinical studies regarding implication of volumetric FDG PET parameters, the significance of FDG uptake in HCC for selecting treatment and predicting treatment response, and the use of radiomics of FDG PET in HCC.

**Key words:** Hepatocellular carcinoma; Fluorodeoxyglucose F18; Positron emission tomography; Staging; Prognosis

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Because of low sensitivity, clinical use of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has been limited in patients with hepatocellular carcinoma (HCC). However, recent studies have shown clinical significance of FDG PET in various ways. The objective of this review is to provide an overview of the current literature regarding FDG PET in HCC and discuss emerging role of FDG PET in aiding management of HCC patients.

Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. *World J Gastroenterol* 2019; In press

**INTRODUCTION**

In 2018, approximately 841000 new cases of liver cancer and 782000 associated deaths occurred worldwide, with liver cancer being the second leading cause of cancer death for males[1]. Hepatocellular carcinoma (HCC) is the most common primary liver cancer, accounting for 75%-85% of cases of liver cancer[1]. HCC is well-known as a highly lethal cancer, showing similar numbers of new cases and cancer deaths[1,2]. Hepatitis B virus (HBV), hepatitis C virus (HCV), and alcohol intake are leading causes of HCC. In developed countries, obesity is an emerging risk factor for HCC[2,3]. The Barcelona Clinical Liver Cancer (BCLC) staging system, endorsed by the European Association for the Study of the Liver and the European Organization for Research and Treatment of Cancer (EASL-EORTC), has been considered as the standard staging system for HCC in clinical practice because it links tumor stage to treatment strategy and has been validated in various different clinical situations[4]. For HCC patients with stage 0 (single tumor < 2 cm) and stage A (single tumor > 2 cm or 3 tumor nodules < 3 cm), curative treatments including surgical resection, liver transplantation, and local ablation have been indicated[4]. For HCC patients with stage B (multinodular tumors), transarterial chemoembolization (TACE) is primarily recommended[4]. For HCC patients with stage C (tumors with portal vein invasion and/or extrahepatic spread), sorafenib is recommended as the first-line treatment[4].

18F-fluorodeoxyglucose (FDG), a glucose analog, is carried into viable cells by glucose transporter and subsequently phosphorylated by hexokinase, which has the same metabolic pathway as glucose[5]. Therefore, FDG on positron emission tomography (PET) has been widely used as an imaging marker of glucose metabolism of normal organs and cancer tissue[6-8]. Since cancer cells show high rates of glycolysis, FDG uptake is increased in cancer tissue[5]. Thus, FDG PET has shown incremental value for diagnosing, staging, predicting prognosis, and restaging diverse kinds of malignant diseases[5,9-11]. In contrast, FDG uptake in HCC varies according to the differentiation of HCC lesion[12,13]. Earlier studies with FDG PET have shown a low diagnostic ability for detecting intrahepatic HCC lesions[12-14], leading to a preconception that FDG PET has limited clinical value in patients with HCC. Nevertheless, diverse attempts have been performed to establish clinical role of FDG PET in HCC and recent studies have shown encouraging results of FDG PET in aiding management of patients with HCC.

In this review, we first summarized characteristics of HCC cells related with FDG uptake and results of studies regarding diagnostic and prognostic values of FDG PET in HCC. We then overviewed recent studies that dealt with volumetric FDG PET parameters, the significance of FDG uptake in HCC for selecting treatment and predicting treatment response, and radiomics of FDG PET in patients with HCC.

**RELATIONSHIP BETWEEN HCC CHARACTERISTICS AND FDG UPTAKE**

Because cancer cells have higher glycolytic rates than normal cells, higher amounts of glucose transporter and hexokinase expression are observed in tumor cells, resulting in increased FDG uptake in cancer lesions[15,16]. However, HCC cells show different expression patterns of proteins related to FDG uptake. HCC has lower level of glucose transporter-1 expression than cholangiocarcinoma and hepatic metastatic lesion[17,18]. Furthermore, high expression of glucose-6-phosphatase which hydrolyzes FDG-6-phosphate to FDG that can be transported out of the cell has been observed in HCC[19]. These different expression patterns contribute to low accumulation of FDG uptake in HCC, thereby reducing sensitivity for detecting HCC lesions[19,20]. Nevertheless, increased glucose transporter expression and hexokinase activity have been demonstrated in high-grade HCC which is positively correlated with FDG uptake[19,21]. Therefore, diverse degrees of FDG uptake have been shown according to the histopathological grade of HCC[12,13,20]. Well-differentiated HCC reveals tumor-to-non-tumor liver uptake ratio (TLR) of around 1.1, indicating difficulty of differentiating FDG uptake of well-differentiated HCC lesion from that of normal liver tissue[20]. Meanwhile, TLR of poorly-differentiated HCC lesion is more than 2.0[20]. A previous study has shown that, by using the degree of FDG accumulation in HCCs, FDG PET could differentiate poorly-differentiated type from well-differentiate type with a sensitivity of 84% and a specificity of 75%[22].

Recent studies have assessed the relationship between HCC characteristics and its FDG uptake at molecular level. Lee *et al*[18] have compared gene expression profiles between HCCs with low FDG uptake and HCCs with high FDG uptake using surgical specimens of 10 HCC patients. In their study, HCCs with high FDG uptake demonstrated different gene expression profiles compared to those with low FDG uptake, showing increased expression of 11 genes particularly related to tumor cell adhesion, invasion, metastasis, anti-tumoral immunity, and chemotherapeutic response. They suggested that HCCs with high FDG uptake might have a more aggressive nature than those with low FDG uptake and that FDG uptake pattern of HCC could reflect potential of tumor progression and metastasis. Another recent study has evaluated the association between FDG uptake and expression of epithelial-mesenchymal transition markers in HCC[21]. Epithelial-mesenchymal transition is the formation process of motile cells from immotile epithelial cells and is known to be involved in the formation of metastatic cancer cells[23]. During epithelial-mesenchymal transition processes, expression levels of mesenchymal markers such as N-cadherin and vimentin increased, while expression of E-cadherin, an epithelial cell junction protein, is lost[21,23]. The recent study demonstrated that, in HCCs with high FDG uptake, expression levels of N-cadherin and vimentin were up-regulated and the expression of E-cadherin was repressed[21]. These significant associations between FDG uptake and expression of epithelial-mesenchymal transition-related proteins in HCC provides a basis for hypothesis that FDG PET might be useful for predicting the risk of extrahepatic metastasis in HCC patients[21].

**FDG PET IN STAGING HCC**

Due to reduced FDG uptake in low-grade HCCs, previous studies have consistently reported a low sensitivity of FDG PET for detecting primary HCC lesions, ranging from 36% to 70%[12-14,20,24-26]. A previous study by Teefey *et al*[27] even reported that FDG PET detected none of cancer lesions in nine patients with HCC who underwent imaging examinations for work-up of liver transplantation. Based on results of these studies, EASL-EORTC guidelines has mentioned that FDG PET scan is not accurate for early diagnosis of HCC[4]. In contrast, FDG PET has shown promising results for detecting extrahepatic metastasis. Because poorly-differentiated HCCs tend to metastasize more frequently, a positive statistical correlation between FDG avidity of primary HCCs and tendency of extrahepatic metastasis has been shown, suggesting that metastatic HCC lesions would also have increased FDG uptake[28]. Extrahepatic metastasis is not an unusual finding in HCC. During staging work-up of HCC, extrahepatic metastases have been found in up to 37% of patients, with the most frequent site of metastasis being the lung, followed by lymph node, bone, and adrenal gland[29,30]. In previous studies, FDG PET has demonstrated high sensitivities of 77%-100% for detecting extrahepatic metastasis[28,31-34]. FDG PET has also shown superior diagnostic ability for detecting bone metastasis compared to bone scintigraphy and incomparable diagnostic accuracy for detecting lymph node metastasis compared to conventional computed tomography (CT) scan[31, 32]. However, FDG PET has a low sensitivity of 20% for detecting pulmonary metastases of less than 1 cm[31]. Therefore, the diagnostic accuracy of chest CT was superior to that of FDG PET for detecting pulmonary metastasis[31].

Clinical utility of imaging modality in staging malignant disease depends on whether the imaging examination can make further shift in cancer staging compared to conventional examinations, thereby, changing treatment modality[35]. In this respect, high diagnostic ability of FDG PET for detecting extrahepatic metastasis might not justify the clinical use of FDG PET in staging HCC. Delineation of additional extrahepatic metastatic lesion by FDG PET might have no significant effect on staging and selecting treatment in HCC patients whose extrahepatic metastases are already found by conventional imaging modalities[35]. The clinical role of FDG PET in staging HCC should be evaluated in terms of ability to change cancer stage and treatment. However, only a small number of studies have assessed this ability of FDG PET in HCC patients, which are summarized in Table 1. In previous studies, FDG PET changed stage and treatment modalities in 1.5%-25% of HCC patients, mainly due to additional detection of extrahepatic metastases[26,34,35]. A recent study by Cho *et al*[35] has enrolled the largest number of patients (457 consecutive patients with HCC) among the studies. In their study, 5.0% of patients with BCLC stage A (6 out of 119 patients) and 1.4% of patients with BCLC stage B (1 out of 71 patients) were upstaged to stage C by FDG PET while none of patients with BCLC stage 0, C, or D had a shift in stage by FDG PET. Furthermore, additional extrahepatic metastases detected by FDG PET were found only in patients with T2 (3 out of 111 patients, 2.7%) and T3 (4 out of 78 patients, 5.1%) classifications of HCC. They suggested that routine staging FDG PET could have the clinical utility in patients with BCLC stage A and B or with T2 and T3 classifications.

**FDG UPTAKE OF HCC AS A PREDICTOR FOR PROGNOSIS**

Because FDG uptake of HCC is associated with tumor differentiation and aggressiveness, it is reasonable to assume that FDG uptake of HCC might have significant association with prognosis[18,19,21]. Therefore, most studies on FDG PET in HCC patients have assessed the prognostic value of FDG PET for predicting clinical outcomes. These studies are summarized in Tables 2-4. In previous studies, visual analysis, maximum FDG uptake of tumor expressed as standardized uptake value (SUV), and TLR have been the most commonly used FDG PET parameters for evaluating FDG uptake of HCCs. Visual assessment and SUV are also commonly used as PET parameters in studies on other malignant diseases[36,37]. TLR has been preferred in studies with HCC patients because TLR is known to correlate more closely with HCC doubling time and represent metabolic activities of HCCs more precisely than SUV[38-40].

In previous studies on HCC patients who underwent curative surgical resection (Table 2), FDG uptake of HCC showed significant association with tumor recurrence, especially early recurrence after surgery, and overall survival, demonstrating worse survival in patients with high FDG uptake[41-46]. However, several studies have failed to show the relationship between FDG PET findings and clinical outcomes on multivariate analysis[47-49]. A recent study by Kim *et al*[49] has retrospectively enrolled 226 patients with HBV-related HCC and evaluated the prognostic value of FDG PET findings. Results of that study revealed that, although positive FDG uptake of HCCs was significantly associated with overall survival, there was no significant difference in disease-free survival according to findings of FDG PET, suggesting that FDG PET could not predict the exact prognosis in patients with HBV-related HCC, because recurrence of HBV-related HCC also included intrahepatic metastasis or *de novo* recurrence. A retrospective multicenter study including 526 patients from nine Korean institutions has made a prognostic prediction model by combining alpha-fetoprotein (AFP)-des-gamma-carboxy prothrombin-tumor volume (ADV) score and FDG PET findings that are all available on staging work-up before surgical resection[50]. The prognostic prediction model exhibited significant differences in tumor recurrence rates and overall survival rates according to ADV scores and PET findings, showing recurrence rate of 67.9% and survival rate of 70.6% in patients with high ADV score and hypermetabolic HCCs while the recurrence rate and survival rate in patients with low ADV score and isometabolic HCCs were 21.1% and 96.6%, respectively. The authors of that study suggested that, by using a combination of ADV scores and FDG PET findings, the risk of HCC recurrence could be reliably predicted.

In previous studies on HCC patients who underwent liver transplantation (Table 3), FDG PET findings consistently showed significant associations with recurrence-free survival and overall survival, demonstrating high recurrence rates after liver transplantation in patients with high FDG uptake[39,51-61]. To select candidates for liver transplantation, the Milan criteria (a solitary tumor no more than 5 cm in diameter or 2 to 3 tumors no more than 3 cm in diameter) and the University of California San Francisco (UCSF) criteria (a solitary tumor up to 6.5 cm in diameter or up to 3 tumors no more than 4.5 cm with a total diameter up to 8 cm) have been commonly used[62,63]. Therefore, most studies have compared the prognostic value of FDG PET with the conventional criteria or combined FDG PET findings with the conventional criteria to further stratify recurrence risk after liver transplantation[51-58,61]. In previous studies, patients beyond the Milan criteria, but, showing negative finding on FDG PET had clinical outcomes comparable to those within the Milan Criteria[52,53,55,61]. Furthermore, even if patients met the Milan criteria, higher recurrence rate was found in those with high FDG uptake of HCCs than that in those with low FDG uptake[39,51]. A previous study by Lee *et al*[58] has proposed new selection criteria with FDG PET finding and total tumor size (10 cm). The new criteria had similar area under the receiver operating characteristic curve value for predicting disease-free survival compared to the Milan criteria or the UCSF criteria[58]. Takada *et al*[60] have performed a retrospective multicenter study with 182 HCC patients who underwent living donor liver transplantation from 16 Japanese medical centers. In that study, FDG PET finding was found to be an independent predictive factor for tumor recurrence along with the Milan criteria and serum AFP level. Patients beyond the Milan criteria but with low serum AFP level and negative FDG PET finding (19%) had similar 5-year recurrence rate to those within the Milan criteria (6%). They also had significantly lower 5-year recurrence rate than those beyond Milan criteria with high serum AFP level and positive PET finding (53%). They suggested that FDG PET could provide additional information for making decisions regarding liver transplantation for HCC patients[60].

The prognostic value of FDG PET has also been assessed in HCC patients treated with palliative treatments including TACE, concurrent chemoradiotherapy (CCRT), radiotherapy, transarterial radioemolization (TARE), and sorafenib (Table 4)[40,64-76]. For patients treated with TACE, CCRT, or radiotherapy, previous studies showed longer progression-free survival and overall survival in patients with low FDG uptake of HCCs, indicating significant associations between FDG avidity of HCCs and clinical outcomes[64-70]. For patients treated with TARE using yttrium-90 (90Y), contradictory results have been shown between studies. Previous studies have revealed longer progression-free survival and overall survival in patients with low FDG uptake of HCCs[72,74], including a recent prospective study with uniform patient cohort[75]. In contrast, one study showed no significant association between FDG uptake of HCCs and survival[73] and another study even showed better progression-free survival in patients with high FDG uptake[71]. This controversy could be due to the small number of enrolled patients with heterogeneous clinical conditions among studies and further larger studies are warranted. Only two studies have evaluated the prognostic value of FDG PET in patients treated with sorafenib monotherapy[40,76]. Both studies showed significantly better survival in patients with low FDG uptake of HCCs[40,76]. However, only a small number of patients are enrolled in both studies and concomitant local therapies are also commonly performed in patients with BCLC stage C. These might have limited analyses in these studies.

Recently, the Korean Society of Nuclear Medicine Clinical Trial Network (KSNM CTN) working group has performed a retrospective multicenter study to assess clinical role of FDG PET in HCC patients[77-80]. They retrospectively recruited 847 patients with newly diagnosed HCC who underwent pretreatment FDG PET/CT from seven university hospitals at Korea and published several studies regarding the prognostic value of FDG PET[77,78]. One of their studies included 317 patients with BCLC stage 0 or A from the cohort and evaluated the predictive value of FDG PET for recurrence-free survival and overall survival[77]. They classified the 317 patients into two groups, a curative therapy cohort (patients who underwent surgical resection, liver transplantation, and local ablation) and a TACE cohort, and assessed the relationship between FDG PET findings and survival in each group. TLR was an independent predictor for both recurrence-free survival and overall survival in the curative therapy cohort. However, TLR failed to show association with survival in the TACE cohort. In the TACE cohort, only the Model for End-Stage Liver Disease score was an independent prognostic factor for overall survival. Considering that only patients who could not undergo curative therapy due to unsuitable HCC location or impaired liver function were included in the TACE cohort, underlying liver function rather than FDG uptake of HCC might have a significant association with survival[77]. Another study by KSNM CTN has evaluated prognostic value of FDG PET in 291 patients with BCLC stage C[78]. They classified patients into two groups; patients with intrahepatic metastasis and patients with extrahepatic metastasis. They showed that higher TLR was associated with extrahepatic metastasis and was an independent predictor for overall survival in both groups. Furthermore, patients with intrahepatic metastases but high TLR had a poor prognosis comparable to patients with extrahepatic metastases and low TLR, suggesting the prognostic significance of primary HCCs uptake irrespective of the extent of metastasis.

In addition to FDG uptake of primary HCC tumors, a recent study by Lee *et al*[81] has evaluated the prognostic value of FDG uptake of portal vein tumor thrombosis. HCC cells can spread to other segments of the liver and distant organs via portal vein; therefore, portal vein tumor thrombosis has a significant impact on the prognosis of HCC patients[81-83]. Lee *et al*[81] have enrolled 166 HCC patients with portal vein tumor thrombosis but no extrahepatic metastasis and compared the prognostic value of FDG uptake of portal vein tumor thrombosis with FDG uptake of primary tumor. Their results revealed that only FDG uptake of portal vein tumor thrombosis was an independent predictor for both progression-free survival and overall survival. They also found that patients with high FDG uptake of portal vein tumor thrombosis had worse survival than those with low FDG uptake, irrespective of the degree of FDG uptake of primary HCCs. Based on these results, they concluded that FDG uptake of portal vein tumor thrombosis rather than FDG uptake of primary tumor should be used to predict clinical outcomes in locally advanced HCC.

**VOLUMETRIC PARAMETERS OF PET AND RECURRENCE PATTERN OF HCC**

In recent decades, volumetric PET indices such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) have been considered as promising PET parameters that can accurately reflect the metabolic burden of malignant lesion[84-86]. SUV and TLR represent only the highest metabolic activity of cancer lesion. On the other hand, MTV is defined as tumor tissue volume that has FDG uptake beyond the intensity of FDG uptake of normal tissue; thus, it can reflect tumor extent[85-87]. TLG is the product of MTV and mean FDG uptake of tumor, which combines both metabolic and volumetric information of the tumor[84,86]. A number of studies have demonstrated that MTV and TLG have higher predictive values for survival than SUV in various malignant diseases during the last two decades[84,86-89]. However, in HCC patients, clinical study that calculated MTV and assessed the prognostic value of MTV was first published in 2015[90]. Since then, only a few studies have evaluated the clinical implication of volumetric PET parameters[91-93].

To measure MTV of cancer lesion, two processes should be performed: delineating tumor lesion from surrounding normal tissue and determining threshold SUV to identify metabolically active tumor volume[90]. Due to heterogeneous and diverse degrees of FDG uptake in HCC and relatively high FDG uptake in normal liver tissue, it is difficult to perform both processes in HCC, thus hindering attempts to measure volumetric PET parameters[90]. Lee *et al*[90] have proposed a novel method using intensity-volume histogram to measure MTV of HCCs that can surpass these limitations. They drew regions of interest over HCC lesion and normal liver tissue and prepared intensity-volume histogram (a plot of volume of a given structure as a function of the SUV) of the HCC lesion and normal liver tissue (Figure 1). Using such intensity-volume histograms of HCC and normal liver tissue, the sum of tumor voxels with higher FDG uptake than normal liver tissue could be calculated for each patient. They calculated MTV2SD (defined as the sum of the tumor voxels over the SUV of the 97.5th percentile of the normal liver tissue voxels) from 59 HCC patients without extrahepatic metastasis. On survival analysis of their study, MTV2SD has more significant prognostic value for predicting progression-free survival and overall survival than TLR.

After publishing the first study with MTV in HCC, authors of the study have tried to assess the clinical value of volumetric PET parameters for predicting recurrence pattern of HCC[92,93]. In HCC patients, extrahepatic metastasis after curative surgical resection is known to be associated with poor prognosis due to limited therapeutic option[42,92]. Furthermore, early recurrence with an interval of less than one year after operation is also known to be a significant indictor for worse survival which is comparable to the survival of patients with extrahepatic metastasis[47,93,94]. In previous studies, tumor factors associated with tumor aggressiveness including tumor stage, size, and grade have been found to be significant predictors for both extrahepatic and early recurrences[47,93,95,96]. FDG uptake of HCC is also related to tumor grade and aggressiveness, therefore, SUV and TLR of HCCs have also been shown to be associated with the risk of extrahepatic and early recurrences[42,45,47,97]. Considering that volumetric PET parameters can more precisely reflect metabolic characteristics and burden of cancer lesions than FDG uptake intensity[86,89], volumetric PET parameters of HCC can have more significant association with recurrence patterns of HCC than SUV or TLR. In two recent studies on the relationship between volumetric PET parameters and recurrence pattern of HCC, the authors have measured MTV and TLG of HCCs using SUV of the 97.5th percentile of the normal liver tissue as threshold SUV and demonstrated that both MTV and TLG have superior prognostic value for predicting both extrahepatic recurrence and early intrahepatic recurrence than TLR in HCC patients after curative surgical resection[92,93]. On the other hand, late intrahepatic recurrence with an interval of more than 1 year after surgery was associated with HCV positivity and serum albumin level, while none of volumetric PET parameters could predict the risk of late intrahepatic recurrence[93]. These results indicate that the risk of both extrahepatic and early intrahepatic recurrences is associated with metabolic tumor burden, while the risk of late intrahepatic recurrence is related to underlying liver function and multicentric tumor formation tendency[93]. Authors of these studies have suggested that volumetric PET parameters of HCC could be used to predict the recurrence pattern and to select patients who might show poor survival after curative surgical resection[92,93].

Kim *et al*[91] have calculated volumetric PET indices and evaluated their prognostic values in 110 HCC patients who underwent liver transplantation. Different from the method used in the study by Lee *et al*[90], they calculated uptake ratio between the maximum SUV of HCCs and background tissue, inferior vena cava (TBRIVC) or normal liver tissue (TBRNL), and used TBRIVC of 2.0 and TBRNL of 1.5 as threshold values for measuring MTV. MTVIVC and MTVNL (defined as the sum of the tumor voxels which had TBRIVC of more than 2.0 and TBRNL of more than 1.5) were measured. With MTV and mean value of TBR, uptake-volume product (UVP) was calculated for each background tissue. Results of their study revealed that both TBRIVC and UVPIVC were independent predictors for recurrence-free survival. The authors suggested that inferior vena cava might be a more reliable background tissue than the normal liver in measuring MTV. They have also suggested that volumetric parameters as well as metabolic activity of HCCs are effective predictors of recurrence after liver transplantation[91].

**USING FDG PET FOR SELECTING TREATMENT OF HCC**

Increased FDG uptake in HCCs reflects aggressive biological activity of tumor and is associated with poor survival[18,19,78]. Therefore, patients with high FDG uptake of HCCs might have poor response to treatment. Previous studies on patients treated with TACE have shown that patients with high FDG uptake have poor response to treatment[65,98]. Furthermore, in HCC patients with high FDG uptake, major hepatectomy that can minimize the possibility of residual tumor rather than minor hepatectomy should be selected to obtain survival benefit[99]. However, in studies on HCC patients treated with external beam radiotherapy, paradoxical relationship between FDG uptake of HCC and treatment response has been shown[100-102]. Kim *et al*[100] have retrospectively enrolled 35 HCC patients with TNM stage III-IV who underwent FDG PET and subsequent radiotherapy with concurrent chemotherapy or TACE. They showed that patients having HCCs of SUV ≥ 2.5 (80%; 16 out of 20 patients) had significantly higher objective response rate to radiotherapy than those with HCCs of SUV < 2.5 (40%; 6 out of 15 patients). Choi *et al*[101] have retrospectively reviewed 45 metastatic bone lesions in 22 HCC patients treated with radiotherapy. They also revealed significantly better infield progression-free survival and infield event-free survival in tumors with SUV of ≥ 3.0 compared to those in tumors with SUV of < 3.0 (1-year progression-free survival, 88% *vs* 34%; 1-year event-free survival, 82% *vs* 52%). Another retrospective study by Jo *et al*[102] has investigated the predictive value of FDG uptake of HCC in 36 HCC patients treated with radiotherapy. In that study, patient group with high SUV (≥ 5.1) showed significantly higher objective tumor response (63.6% *vs* 36.4%) than patient group with low SUV (< 5.1). In spite of high tumor response, patient group with high SUV had worse overall survival mainly due to the occurrence of distant metastasis. Authors of these studies have explained this paradoxical relationship by radiosensitivity of highly proliferating tumor[100,102]. In a previous study, FDG uptake of HCCs has shown a positive association with tumor doubling time[38]. Because rapidly proliferating tumors are radiosensitive, HCCs with high FDG uptake are considered to have better response to radiotherapy than those with low uptake[100,102]. However, HCCs with high FDG uptake also have high risk for early recurrence and distant metastasis[92,93]. Therefore, viable tumor cells in residual lesions after radiotherapy could spread more rapidly and more frequently to extrahepatic organs, resulting in worse overall survival[102].

Results of these studies on radiotherapy have indicated that HCCs might show different responses to treatment according to the degree of FDG uptake of HCC. In this respect, a recent study reported by KSNM CTN working group has demonstrated interesting results[79]. The study retrospectively enrolled 214 intermediate-to-advanced stage patients without extrahepatic metastasis who underwent CCRT or TACE as an initial treatment from a cohort of 847 HCC patients from seven hospitals. Authors of the study have classified these enrolled patients into two patient groups according to TLR of HCCs (patient groups with TLR > 2.0 and ≤ 2.0) and compared clinical outcomes between patients treated with CCRT and TACE for each patient group. In patient group with TLR > 2.0, patients treated with CCRT demonstrated significantly longer progression-free survival and overall survival than those treated with TACE. Meanwhile, for patient group with TLR ≤ 2.0, there were no significant differences in progression-free survival or overall survival between patients treated with CCRT and those treated with TACE. The authors suggested that, for patients with high FDG uptake, multimodality treatment including radiotherapy could be more effective in tumor control while HCCs with low FDG uptake seemed to be less affected by the treatment modality. Considering that HCCs with low and high FDG uptake have different tumor characteristics, genetic disposition, and recurrence pattern[18,19,21,93], different treatment strategy might be needed according to findings of FDG PET in HCC patients. However, as the study by KSNM CTN working group[79] was retrospectively performed, further prospective study is needed to validate the role of FDG PET in selecting treatment modality.

**RADIOMICS OF FDG PET IN HCC**

Currently, the concept of radiomics has been widespread in the field of oncology[103]. Radiomics is defined as high-throughput extraction of a large number of imaging features that can comprehensively quantify tumor phenotypes[104,105]. Textural features of cancer tissue on medical images are associated with genomic and proteomic expression patterns of cancer cells and many studies have revealed that radiomics signature made of textural features can independently predict prognosis in diverse cancers including head and neck cancer, lung cancer, breast cancer, and esophageal cancer[103,105,106]. However, in HCC, only a single study by Blanc-Durand *et al*[107] has evaluated the prognostic value of textural features of HCC. In radiomics study of FDG PET, image preprocessing including the process of delineation and segmentation of tumor lesion is essential for textural analysis of PET images[105,108]. Considering that HCC lesions have heterogeneous and variable FDG uptake, it is difficult to delineate HCC lesions from normal liver tissue accurately as shown in aforementioned section with volumetric PET parameters[90]. This might act as the main hurdle to perform textural analysis in FDG PET images of HCC. Blanc-Durand *et al*[107] have retrospectively enrolled 47 HCC patients who underwent pretreatment FDG PET and subsequent transarterial radioembolization using 90Y. Using PET images of whole liver including both tumor and non-tumoral liver for textural analysis, they extracted 108 textural features from these images. They claimed that, by introducing whole-liver in the radiomics model, both hepatic function and HCC biology could be integrated into one system. With mainly using two textural features, strength (a textural feature describing pattern perceivability, its value is high when intensity pattern is easily defined and visible) and variance (a textural feature describing a deviation from the mean), predictive radiomics scoring systems for progression-free survival and overall survival were generated. On multivariate survival analysis, these radiomics scoring systems turned out to be independent negative predictors for both progression-free survival and overall survival. Moreover, prognostic values of radiomics scoring systems did not differ even after stratification by BCLC staging and tumor size. The authors suggested that whole-liver radiomics approach representing a balance between normal liver tissue and tumor burden could provide prognostic information for HCC patients. However, further studies with more patients are warranted to validate the methodology and results of their study.

**CONCLUSION**

FDG PET is a non-invasive imaging method that can evaluate biological activity of HCC. Although FDG PET has been considered to have low sensitivity for detecting HCCs, it can detect unexpected extrahepatic metastasis with incremental prognostic value for predicting survival. Furthermore, recent studies have demonstrated encouraging results of FDG PET for predicting recurrence pattern and aiding the selection of treatment for HCC. With development of new analytic methods of FDG PET images such as volumetric and textural analyses, clinical use of FDG PET in HCC patients would be continuously evolving. FDG PET should be considered as an imaging biomarker that can provide information for selecting management strategies in HCC patients rather than a simple diagnostic imaging modality with a limited sensitivity.

**REFERENCES**

1 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 **Yang JD**, Roberts LR. Hepatocellular carcinoma: A global view. *Nat Rev Gastroenterol Hepatol* 2010; **7**: 448-458 [PMID: 20628345 DOI: 10.1038/nrgastro.2010.100]

3 **Marengo A**, Rosso C, Bugianesi E. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. *Annu Rev Med* 2016; **67**: 103-117 [PMID: 26473416 DOI: 10.1146/annurev-med-090514-013832]

4 **European Association For The Study Of The Liver**; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012; **56**: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]

5 **Kelloff GJ**, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL, Sullivan DC. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. *Clin Cancer Res* 2005; **11**: 2785-2808 [PMID: 15837727 DOI: 10.1158/1078-0432.ccr-04-2626]

6 **Lee JW**, Lee MS, Chung IK, Son MW, Cho YS, Lee SM. Clinical implication of FDG uptake of bone marrow on PET/CT in gastric cancer patients with surgical resection. *World J Gastroenterol* 2017; **23**: 2385-2395 [PMID: 28428718 DOI: 10.3748/wjg.v23.i13.2385]

7 **Lee JW**, Lee SM, Chung YA. Prognostic value of CT attenuation and FDG uptake of adipose tissue in patients with pancreatic adenocarcinoma. *Clin Radiol* 2018; **73**: 1056.e1-1056.e10 [PMID: 30077337 DOI: 10.1016/j.crad.2018.07.094]

8 **Pourhassan Shamchi S**, Khosravi M, Taghvaei R, Zirakchian Zadeh M, Paydary K, Emamzadehfard S, Werner TJ, Høilund-Carlsen PF, Alavi A. Normal patterns of regional brain 18F-FDG uptake in normal aging. *Hell J Nucl Med* 2018; **21**: 175-180 [PMID: 30411727 DOI: 10.1967/S002449910902]

9 **Cheng G**, Huang H. Prognostic Value of 18F-Fluorodeoxyglucose PET/Computed Tomography in Non-Small-Cell Lung Cancer. *PET Clin* 2018; **13**: 59-72 [PMID: 29157386 DOI: 10.1016/j.cpet.2017.08.006]

10 **Diao W**, Tian F, Jia Z. The prognostic value of SUVmax measuring on primary lesion and ALN by 18F-FDG PET or PET/CT in patients with breast cancer. *Eur J Radiol* 2018; **105**: 1-7 [PMID: 30017264 DOI: 10.1016/j.ejrad.2018.05.014]

11 **Lee Y**, Yoo IR, Boo SH, Kim H, Park HL, Hyun O J. The Role of F-18 FDG PET/CT in Intrahepatic Cholangiocarcinoma. *Nucl Med Mol Imaging* 2017; **51**: 69-78 [PMID: 28250860 DOI: 10.1007/s13139-016-0440-y]

12 **Khan MA**, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, Collins BT, Di Bisceglie AM. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. *J Hepatol* 2000; **32**: 792-797 [PMID: 10845666 DOI: 10.1016/S0168-8278(00)80248-2]

13 **Trojan J**, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, Zeuzem S. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. *Am J Gastroenterol* 1999; **94**: 3314-3319 [PMID: 10566736 DOI: 10.1111/j.1572-0241.1999.01544.x]

14 **Delbeke D**, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. *Arch Surg*1998; **133**: 510-5; discussion 515-6 [PMID: 9605913 DOI: 10.1001/archsurg.133.5.510]

15 **Ong LC**, Jin Y, Song IC, Yu S, Zhang K, Chow PK. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II. *Acta Radiol* 2008; **49**: 1145-1153 [PMID: 18979289 DOI: 10.1080/02841850802482486]

16 **Zhao S**, Kuge Y, Mochizuki T, Takahashi T, Nakada K, Sato M, Takei T, Tamaki N. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. *J Nucl Med* 2005; **46**: 675-682 [PMID: 15809491]

17 **Zimmerman RL**, Burke M, Young NA, Solomides CC, Bibbo M. Diagnostic utility of Glut-1 and CA 15-3 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine-needle aspiration. *Cancer* 2002; **96**: 53-57 [PMID: 11836704 DOI: 10.1102/cncr.10309]

18 **Lee JD**, Yang WI, Park YN, Kim KS, Choi JS, Yun M, Ko D, Kim TS, Cho AE, Kim HM, Han KH, Im SS, Ahn YH, Choi CW, Park JH. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. *J Nucl Med* 2005; **46**: 1753-1759 [PMID: 16204727]

19 **Torizuka T**, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, Tanaka A, Yamaoka Y, Yamamoto K, Konishi J. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. *J Nucl Med* 1995; **36**: 1811-1817 [PMID: 7562048]

20 **Ho CL**, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. *J Nucl Med* 2003; **44**: 213-221 [PMID: 12571212]

21 **Lee M**, Jeon JY, Neugent ML, Kim JW, Yun M. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma. *Clin Exp Metastasis* 2017; **34**: 251-260 [PMID: 28429188 DOI: 10.1007/s10585-017-9847-9]

22 **Ferda J**, Ferdová E, Baxa J, Kreuzberg B, Daum O, Třeška V, Skalický T. The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing, grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiography. *Anticancer Res* 2015; **35**: 2241-2246 [PMID: 25862885]

23 **Zeisberg M**, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. *J Clin Invest* 2009; **119**: 1429-1437 [PMID: 19487819 DOI: 10.1172/JCI36183]

24 **Wudel LJ Jr**, Delbeke D, Morris D, Rice M, Washington MK, Shyr Y, Pinson CW, Chapman WC. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. *Am Surg* 2003; **69**: 117-24; discussion 124-6 [PMID: 12641351]

25 **Ijichi H**, Shirabe K, Taketomi A, Yoshizumi T, Ikegami T, Mano Y, Aishima S, Abe K, Honda H, Maehara Y. Clinical usefulness of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma. *Hepatol Res* 2013; **43**: 481-487 [PMID: 23145869 DOI: 10.1111/j.1872-034X.2012.01107.x]

26 **Kawamura E**, Shiomi S, Kotani K, Kawabe J, Hagihara A, Fujii H, Uchida-Kobayashi S, Iwai S, Morikawa H, Enomoto M, Murakami Y, Tamori A, Kawada N. Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma. *J Gastroenterol Hepatol* 2014; **29**: 1722-1727 [PMID: 24730671 DOI: 10.1111/jgh.12611]

27 **Teefey SA**, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM, Ritter JH. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. *Radiology* 2003; **226**: 533-542 [PMID: 12563151 DOI: 10.1148/radiol.2262011980]

28 **Ho CL**, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. *J Nucl Med* 2007; **48**: 902-909 [PMID: 17504862 DOI: 10.2967/jnumed.106.036673]

29 **Katyal S**, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. *Radiology* 2000; **216**: 698-703 [PMID: 10966697 DOI: 10.1148/radiology.216.3.r00se24698]

30 **Uka K**, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, Hiramatsu A, Kodama H, Takahashi S, Chayama K. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. *World J Gastroenterol* 2007; **13**: 414-420 [PMID: 17230611 DOI: 10.3748/wjg.v13.i3.414]

31 **Lee JE**, Jang JY, Jeong SW, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Jin SY, Choi DL. Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan. *World J Gastroenterol* 2012; **18**: 2979-2987 [PMID: 22736922 DOI: 10.3748/wjg.v18.i23.2979]

32 **Sugiyama M**, Sakahara H, Torizuka T, Kanno T, Nakamura F, Futatsubashi M, Nakamura S. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. *J Gastroenterol* 2004; **39**: 961-968 [PMID: 15549449 DOI: 10.1007/s00535-004-1427-5]

33 **Park JW**, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. *J Nucl Med* 2008; **49**: 1912-1921 [PMID: 18997056 DOI: 10.2967/jnumed.108.055087]

34 **Yoon KT**, Kim JK, Kim DY, Ahn SH, Lee JD, Yun M, Rha SY, Chon CY, Han KH. Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. *Oncology* 2007; **72** Suppl 1: 104-110 [PMID: 18087190 DOI: 10.1159/000111715]

35 **Cho Y**, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ. Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma? *PLoS One* 2014; **9**: e105679 [PMID: 25153834 DOI: 10.1371/journal.pone.0105679]

36 **Lee JW**, Lee SM, Lee MS, Shin HC. Role of ¹⁸F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection. *Eur J Nucl Med Mol Imaging* 2012; **39**: 1425-1434 [PMID: 22673973 DOI: 10.1007/s00259-012-2164-2]

37 **Lee JW**, Na JO, Kang DY, Lee SY, Lee SM. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection. *Clin Lung Cancer* 2017; **18**: 198-206 [PMID: 27495385 DOI: 10.1016/j.cllc.2016.07.001]

38 **Shiomi S**, Nishiguchi S, Ishizu H, Iwata Y, Sasaki N, Tamori A, Habu D, Takeda T, Kubo S, Ochi H. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. *Am J Gastroenterol* 2001; **96**: 1877-1880 [PMID: 11419843 DOI: 10.1111/j.1572-0241.2001.03888.x]

39 **Lee JW**, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK, Lee MC, Lee DS. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. *J Nucl Med* 2009; **50**: 682-687 [PMID: 19372474 DOI: 10.2967/jnumed.108.060574]

40 **Sung PS**, Park HL, Yang K, Hwang S, Song MJ, Jang JW, Choi JY, Yoon SK, Yoo IR, Bae SH. 18F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment. *Eur J Nucl Med Mol Imaging* 2018; **45**: 384-391 [PMID: 29124280 DOI: 10.1007/s00259-017-3871-5]

41 **Hatano E**, Ikai I, Higashi T, Teramukai S, Torizuka T, Saga T, Fujii H, Shimahara Y. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. *World J Surg* 2006; **30**: 1736-1741 [PMID: 16850145 DOI: 10.1007/s00268-005-0791-5]

42 **Kitamura K**, Hatano E, Higashi T, Seo S, Nakamoto Y, Yamanaka K, Iida T, Taura K, Yasuchika K, Uemoto S. Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. *Ann Surg Oncol* 2012; **19**: 156-162 [PMID: 21850564 DOI: 10.1245/s10434-011-1990-y]

43 **Han JH**, Kim DG, Na GH, Kim EY, Lee SH, Hong TH, You YK. Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma. *World J Gastroenterol* 2014; **20**: 17132-17140 [PMID: 25493027 DOI: 10.3748/wjg.v20.i45.17132]

44 **Cho KJ**, Choi NK, Shin MH, Chong AR. Clinical usefulness of FDG-PET in patients with hepatocellular carcinoma undergoing surgical resection. *Ann Hepatobiliary Pancreat Surg* 2017; **21**: 194-198 [PMID: 29264581 DOI: 10.14701/ahbps.2017.21.4.194]

45 **Lim C**, Salloum C, Chalaye J, Lahat E, Costentin CE, Osseis M, Itti E, Feray C, Azoulay D. 18F-FDG PET/CT predicts microvascular invasion and early recurrence after liver resection for hepatocellular carcinoma: A prospective observational study. *HPB (Oxford)* 2018; : [PMID: 30401520 DOI: 10.1016/j.hpb.2018.10.007]

46 **Yoh T**, Seo S, Ogiso S, Kawai T, Okuda Y, Ishii T, Taura K, Higashi T, Nakamoto Y, Hatano E, Kaido T, Uemoto S. Proposal of a New Preoperative Prognostic Model for Solitary Hepatocellular Carcinoma Incorporating 18F-FDG-PET Imaging with the ALBI Grade. *Ann Surg Oncol* 2018; **25**: 542-549 [PMID: 29168098 DOI: 10.1245/s10434-017-6262-z]

47 **Ahn SG**, Kim SH, Jeon TJ, Cho HJ, Choi SB, Yun MJ, Lee JD, Kim KS. The role of preoperative [18F]fluorodeoxyglucose positron emission tomography in predicting early recurrence after curative resection of hepatocellular carcinomas. *J Gastrointest Surg* 2011; **15**: 2044-2052 [PMID: 21904962 DOI: 10.1007/s11605-011-1660-1]

48 **Baek YH**, Lee SW, Jeong YJ, Jeong JS, Roh YH, Han SY. Tumor-to-muscle ratio of 8F-FDG PET for predicting histologic features and recurrence of HCC. *Hepatogastroenterology* 2015; **62**: 383-388 [PMID: 25916068]

49 **Kim JM**, Kwon CHD, Joh JW, Sinn DH, Choi GS, Paik SW. Prognosis of preoperative positron emission tomography uptake in hepatectomy patients. *Ann Surg Treat Res* 2018; **94**: 183-189 [PMID: 29629352 DOI: 10.4174/astr.2018.94.4.183]

50 **Hwang S**, Joh JW, Wang HJ, Kim DG, Kim KS, Suh KS, Kim SH, Yu HC, Cho CK, Lee YJ, Kim KH, Kim JM, Kim BW, Lee SG. Prognostic Prediction Models for Resection of Large Hepatocellular Carcinoma: A Korean Multicenter Study. *World J Surg* 2018; **42**: 2579-2591 [PMID: 29340726 DOI: 10.1007/s00268-018-4468-2]

51 **Yang SH**, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, Yi NJ, Lee KU. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. *Liver Transpl* 2006; **12**: 1655-1660 [PMID: 16964589 DOI: 10.1002/lt.20861]

52 **Kornberg A**, Freesmeyer M, Bärthel E, Jandt K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschild D, Settmacher U. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. *Am J Transplant* 2009; **9**: 592-600 [PMID: 19191771 DOI: 10.1111/j.1600-6143.2008.02516.x]

53 **Kornberg A**, Küpper B, Tannapfel A, Büchler P, Krause B, Witt U, Gottschild D, Friess H. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation. *Liver Transpl* 2012; **18**: 53-61 [PMID: 21850692 DOI: 10.1002/lt.22416]

54 **Lee SD**, Kim SH, Kim YK, Kim C, Kim SK, Han SS, Park SJ. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. *Transpl Int* 2013; **26**: 50-60 [PMID: 23106431 DOI: 10.1111/j.1432-2277.2012.01572.x]

55 **Detry O**, Govaerts L, Deroover A, Vandermeulen M, Meurisse N, Malenga S, Bletard N, Mbendi C, Lamproye A, Honoré P, Meunier P, Delwaide J, Hustinx R. Prognostic value of (18)F-FDG PET/CT in liver transplantation for hepatocarcinoma. *World J Gastroenterol* 2015; **21**: 3049-3054 [PMID: 25780305 DOI: 10.3748/wjg.v21.i10.3049]

56 **Hong G**, Suh KS, Suh SW, Yoo T, Kim H, Park MS, Choi Y, Paeng JC, Yi NJ, Lee KW. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. *J Hepatol* 2016; **64**: 852-859 [PMID: 26658686 DOI: 10.1016/j.jhep.2015.11.033]

57 **Hsu CC**, Chen CL, Wang CC, Lin CC, Yong CC, Wang SH, Liu YW, Lin TL, Lee WF, Lin YH, Chan YC, Wu YJ, Eng HL, Cheng YF. Combination of FDG-PET and UCSF Criteria for Predicting HCC Recurrence After Living Donor Liver Transplantation. *Transplantation* 2016; **100**: 1925-1932 [PMID: 27306534 DOI: 10.1097/TP.0000000000001297]

58 **Lee SD**, Lee B, Kim SH, Joo J, Kim SK, Kim YK, Park SJ. Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria. *World J Transplant*2016; **6**: 411-422 [PMID: 27358787 DOI: 10.5500/wjt.v6.i2.411]

59 **Kornberg A**, Witt U, Schernhammer M, Kornberg J, Ceyhan GO, Mueller K, Friess H, Thrum K. Combining 18F-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma. *Sci Rep* 2017; **7**: 14176 [PMID: 29074969 DOI: 10.1038/s41598-017-14430-9]

60 **Takada Y**, Kaido T, Shirabe K, Nagano H, Egawa H, Sugawara Y, Taketomi A, Takahara T, Wakabayashi G, Nakanishi C, Kawagishi N, Kenjo A, Gotoh M, Toyoki Y, Hakamada K, Ohtsuka M, Akamatsu N, Kokudo N, Takeda K, Endo I, Takamura H, Okajima H, Wada H, Kubo S, Kuramitsu K, Ku Y, Ishiyama K, Ohdan H, Ito E, Maehara Y, Honda M, Inomata Y, Furukawa H, Uemoto S, Yamaue H, Miyazaki M, Takada T; LTx-PET study group of the Japanese Society of Hepato-Biliary-Pancreatic Surgery and the Japanese Liver Transplantation Society. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study. *J Hepatobiliary Pancreat Sci* 2017; **24**: 49-57 [PMID: 27806426 DOI: 10.1002/jhbp.412]

61 **Ye YF**, Wang W, Wang T, Yu J, Geng L, Yu SF, Yan S, Zheng SS. Role of [18F] fludeoxyglucose positron emission tomography in the selection of liver transplantation candidates in patients with hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int* 2017; **16**: 257-263 [PMID: 28603093 DOI: 10.1016/S1499-3872(17)60011-0]

62 **Mazzaferro V**, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; **334**: 693-699 [PMID: 8594428 DOI: 10.1056/nejm199603143341104]

63 **Yao FY**, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. *Hepatology* 2001; **33**: 1394-1403 [PMID: 11391528 DOI: 10.1053/jhep.2001.24563]

64 **Song MJ**, Bae SH, Yoo IeR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of ¹⁸F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. *World J Gastroenterol* 2012; **18**: 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215]

65 **Song MJ**, Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. *Eur J Nucl Med Mol Imaging* 2013; **40**: 865-873 [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2]

66 **Ma W**, Jia J, Wang S, Bai W, Yi J, Bai M, Quan Z, Yin Z, Fan D, Wang J, Han G. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). *Theranostics* 2014; **4**: 736-744 [PMID: 24883123 DOI: 10.7150/thno.8725]

67 **Kim MJ**, Kim YS, Cho YH, Jang HY, Song JY, Lee SH, Jeong SW, Kim SG, Jang JY, Kim HS, Kim BS, Lee WH, Park JM, Lee JM, Lee MH, Choi DL. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization. *Korean J Intern Med* 2015; **30**: 308-315 [PMID: 25995661 DOI: 10.3904/kjim.2015.30.3.308]

68 **Kim BK**, Kang WJ, Kim JK, Seong J, Park JY, Kim DY, Ahn SH, Lee DY, Lee KH, Lee JD, Han KH. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. *Cancer* 2011; **117**: 4779-4787 [PMID: 21469082 DOI: 10.1002/cncr.26099]

69 **Huang WY**, Kao CH, Huang WS, Chen CM, Chang LP, Lee MS, Chao HL, Chiu CH, Lo CH, Jen YM. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy. *J Nucl Med* 2013; **54**: 1710-1716 [PMID: 23970365 DOI: 10.2967/jnumed.112.119370]

70 **Rhee WJ**, Hwang SH, Byun HK, Yun M, Han KH, Seong J. Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and 18 F-fluoro-2-deoxyglucose positron emission tomography. *Liver Int* 2017; **37**: 592-599 [PMID: 27804192 DOI: 10.1111/liv.13297]

71 **Kucuk ON**, Soydal C, Araz M, Bilgic S, Ibis E. Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT. *Clin Nucl Med* 2013; **38**: e283-e289 [PMID: 23531737 DOI: 10.1097/RLU.0b013e3182867f17]

72 **Sabet A**, Ahmadzadehfar H, Bruhman J, Sabet A, Meyer C, Wasmuth JC, Pieper CC, Biersack HJ, Ezziddin S. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET. *Nuklearmedizin* 2014; **53**: 39-45 [PMID: 24777354 DOI: 10.3413/Nukmed-0622-13-09]

73 **Soydal C**, Keskin O, Kucuk ON, Ozkan E, Bilgic S, Idilman R, Kir MK. Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy. *Ann Nucl Med* 2015; **29**: 426-430 [PMID: 25783289 DOI: 10.1007/s12149-015-0962-x]

74 **Abuodeh Y**, Naghavi AO, Ahmed KA, Venkat PS, Kim Y, Kis B, Choi J, Biebel B, Sweeney J, Anaya DA, Kim R, Malafa M, Frakes JM, Hoffe SE, El-Haddad G. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. *World J Gastroenterol* 2016; **22**: 10406-10414 [PMID: 28058021 DOI: 10.3748/wjg.v22.i47.10406]

75 **Jreige M**, Mitsakis P, Van Der Gucht A, Pomoni A, Silva-Monteiro M, Gnesin S, Boubaker A, Nicod-Lalonde M, Duran R, Prior JO, Denys A, Schaefer N. 18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma. *Eur J Nucl Med Mol Imaging* 2017; **44**: 1215-1222 [PMID: 28233086 DOI: 10.1007/s00259-017-3653-0]

76 **Lee JH**, Park JY, Kim DY, Ahn SH, Han KH, Seo HJ, Lee JD, Choi HJ. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. *Liver Int* 2011; **31**: 1144-1149 [PMID: 21745288 DOI: 10.1111/j.1478-3231.2011.02541.x]

77 **Hyun SH**, Eo JS, Lee JW, Choi JY, Lee KH, Na SJ, Hong IK, Oh JK, Chung YA, Song BI, Kim TS, Kim KS, Moon DH, Yun M. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study. *Eur J Nucl Med Mol Imaging* 2016; **43**: 1638-1645 [PMID: 26936852 DOI: 10.1007/s00259-016-3348-y]

78 **Na SJ**, Oh JK, Hyun SH, Lee JW, Hong IK, Song BI, Kim TS, Eo JS, Lee SW, Yoo IR, Chung YA, Yun M. 18F-FDG PET/CT Can Predict Survival of Advanced Hepatocellular Carcinoma Patients: A Multicenter Retrospective Cohort Study. *J Nucl Med* 2017; **58**: 730-736 [PMID: 27789714 DOI: 10.2967/jnumed.116.182022]

79 **Lee JW**, Oh JK, Chung YA, Na SJ, Hyun SH, Hong IK, Eo JS, Song BI, Kim TS, Kim DY, Kim SU, Moon DH, Lee JD, Yun M. Prognostic Significance of ¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study. *J Nucl Med* 2016; **57**: 509-516 [PMID: 26742711 DOI: 10.2967/jnumed.115.167338]

80 **Hyun SH**, Eo JS, Song BI, Lee JW, Na SJ, Hong IK, Oh JK, Chung YA, Kim TS, Yun M. Preoperative prediction of microvascular invasion of hepatocellular carcinoma using 18F-FDG PET/CT: a multicenter retrospective cohort study. *Eur J Nucl Med Mol Imaging* 2018; **45**: 720-726 [PMID: 29167923 DOI: 10.1007/s00259-017-3880-4]

81 **Lee JW**, Hwang SH, Kim DY, Han KH, Yun M. Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma. *Clin Nucl Med* 2017; **42**: e35-e40 [PMID: 27775940 DOI: 10.1097/rlu.0000000000001422]

82 **Toyosaka A**, Okamoto E, Mitsunobu M, Oriyama T, Nakao N, Miura K. Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel. *Am J Gastroenterol* 1996; **91**: 1610-1615 [PMID: 8759671]

83 **Addario L**, Tritto G, Cavaglià E, Amodio F, Giannelli E, Di Costanzo GG. Preserved liver function, portal thrombosis and absence of oesophageal varices are risk factors for metastasis of hepatocellular carcinoma. *Dig Liver Dis* 2011; **43**: 319-324 [PMID: 20952262 DOI: 10.1016/j.dld.2010.09.003]

84 **Larson SM**, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. *Clin Positron Imaging* 1999; **2**: 159-171 [PMID: 14516540]

85 **Choi MY**, Lee KM, Chung JK, Lee DS, Jeong JM, Park JG, Kim JH, Lee MC. Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer. *Ann Nucl Med* 2005; **19**: 123-129 [PMID: 15909492]

86 **Lee JW**, Kang CM, Choi HJ, Lee WJ, Song SY, Lee JH, Lee JD. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer. *J Nucl Med* 2014; **55**: 898-904 [PMID: 24711649 DOI: 10.2967/jnumed.113.131847]

87 **Im HJ**, Bradshaw T, Solaiyappan M, Cho SY. Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better? *Nucl Med Mol Imaging* 2018; **52**: 5-15 [PMID: 29391907 DOI: 10.1007/s13139-017-0493-6]

88 **Hyun SH**, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH, Kim BT. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. *Ann Surg* 2013; **257**: 364-370 [PMID: 22968069 DOI: 10.1097/SLA.0b013e318262a6ec]

89 **Ryu IS**, Kim JS, Roh JL, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas. *J Nucl Med* 2013; **54**: 1032-1038 [PMID: 23670902 DOI: 10.2967/jnumed.112.116053]

90 **Lee JW**, Yun M, Cho A, Han KH, Kim DY, Lee SM, Lee JD. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis. *Ann Nucl Med* 2015; **29**: 400-408 [PMID: 25652647 DOI: 10.1007/s12149-015-0956-8]

91 **Kim YI**, Paeng JC, Cheon GJ, Suh KS, Lee DS, Chung JK, Kang KW. Prediction of Posttransplantation Recurrence of Hepatocellular Carcinoma Using Metabolic and Volumetric Indices of 18F-FDG PET/CT. *J Nucl Med* 2016; **57**: 1045-1051 [PMID: 26985057 DOI: 10.2967/jnumed.115.170076]

92 **Hwang SH**, Lee JW, Cho HJ, Kim KS, Choi GH, Yun M. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Very Early and Early Hepatocellular Carcinoma. *Clin Nucl Med* 2017; **42**: 34-39 [PMID: 27775949 DOI: 10.1097/rlu.0000000000001449]

93 **Lee JW**, Hwang SH, Kim HJ, Kim D, Cho A, Yun M. Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection. *Eur J Nucl Med Mol Imaging* 2017; **44**: 1984-1994 [PMID: 28695236 DOI: 10.1007/s00259-017-3764-7]

94 **Shimada M**, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. *Gastroenterology* 1996; **111**: 720-726 [PMID: 8780578]

95 **Poon RT**, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. *Cancer* 2000; **89**: 500-507 [PMID: 10931448]

96 **Uchino K**, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H, Koike K. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. *Cancer* 2011; **117**: 4475-4483 [PMID: 21437884 DOI: 10.1002/cncr.25960]

97 **Ochi H**, Hirooka M, Hiraoka A, Koizumi Y, Abe M, Sogabe I, Ishimaru Y, Furuya K, Miyagawa M, Kawasaki H, Michitaka K, Takada Y, Mochizuki T, Hiasa Y. 18F-FDG-PET/CT predicts the distribution of microsatellite lesions in hepatocellular carcinoma. *Mol Clin Oncol* 2014; **2**: 798-804 [PMID: 25054048 DOI: 10.3892/mco.2014.328]

98 **Park S**, Kim TS, Kang SH, Kim HB, Park JW, Kim SK. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization. *Medicine* (Baltimore) 2018; **97**: e12311 [PMID: 30212970 DOI: 10.1097/MD.0000000000012311]

99 **Ahn SG**, Jeon TJ, Lee SD, Kim SH, Cho HJ, Yun M, Park YN, Lee JD, Park SJ, Kim KS. A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function. *Eur J Surg Oncol* 2013; **39**: 964-973 [PMID: 23859893 DOI: 10.1016/j.ejso.2013.06.019]

100 **Kim JW**, Seong J, Yun M, Lee IJ, Yoon HI, Cho HJ, Han KH. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. *Int J Radiat Oncol Biol Phys* 2012; **82**: 1172-1178 [PMID: 21570203 DOI: 10.1016/j.ijrobp.2010.11.076]

101 **Choi SH**, Chang JS, Jeong YH, Lee Y, Yun M, Seong J. FDG-PET predicts outcomes of treated bone metastasis following palliative radiotherapy in patients with hepatocellular carcinoma. *Liver Int* 2014; **34**: 1118-1125 [PMID: 24528941 DOI: 10.1111/liv.12487]

102 **Jo IY**, Son SH, Kim M, Sung SY, Won YK, Kang HJ, Lee SJ, Chung YA, Oh JK, Kay CS. Prognostic value of pretreatment (18)F-FDG PET-CT in radiotherapy for patients with hepatocellular carcinoma. *Radiat Oncol J* 2015; **33**: 179-187 [PMID: 26484301 DOI: 10.3857/roj.2015.33.3.179]

103 **Aerts HJ**, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ, Lambin P. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. *Nat Commun* 2014; **5**: 4006 [PMID: 24892406 DOI: 10.1038/ncomms5006]

104 **Lambin P**, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, Zegers CM, Gillies R, Boellard R, Dekker A, Aerts HJ. Radiomics: extracting more information from medical images using advanced feature analysis. *Eur J Cancer* 2012; **48**: 441-446 [PMID: 22257792 DOI: 10.1016/j.ejca.2011.11.036]

105 **Lee JW**, Lee SM. Radiomics in Oncological PET/CT: Clinical Applications. *Nucl Med Mol Imaging* 2018; **52**: 170-189 [PMID: 29942396 DOI: 10.1007/s13139-017-0500-y]

106 **Hatt M**, Majdoub M, Vallières M, Tixier F, Le Rest CC, Groheux D, Hindié E, Martineau A, Pradier O, Hustinx R, Perdrisot R, Guillevin R, El Naqa I, Visvikis D. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. *J Nucl Med* 2015; **56**: 38-44 [PMID: 25500829 DOI: 10.2967/jnumed.114.144055]

107 **Blanc-Durand P**, Van Der Gucht A, Jreige M, Nicod-Lalonde M, Silva-Monteiro M, Prior JO, Denys A, Depeursinge A, Schaefer N. Signature of survival: a 18F-FDG PET based whole-liver radiomic analysis predicts survival after 90Y-TARE for hepatocellular carcinoma. *Oncotarget* 2017; **9**: 4549-4558 [PMID: 29435123 DOI: 10.18632/oncotarget.23423]

108 **Choi H**. Deep Learning in Nuclear Medicine and Molecular Imaging: Current Perspectives and Future Directions. *Nucl Med Mol Imaging* 2018; **52**: 109-118 [PMID: 29662559 DOI: 10.1007/s13139-017-0504-7]

**P-Reviewer:** Tsoulfas G

**S-Editor:** Ma RY **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** South Korea

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 An example of the method for measuring metabolic tumor volume based on intensity-volume histogram from reference[88] with permission**. Maximal intensity projection (A) and transaxial image (C) of 18F-fluorodexoyglucose (FDG) positron emission tomography (PET) and contrast-enhanced computed tomography image (B) showed a single hepatocellular carcinoma (HCC) with moderately increased FDG uptake. Regions of interest of HCC (red) and normal liver tissue (blue) are manually drawn on transaxial PET images (D). Cumulative intensity-volume histogram plots for HCC (red) and normal liver tissue (blue) are calculated from regions of interest. Standardized uptake value of the 97.5th percentile of the voxels of the normal liver tissue was 2.7 (blue box) and the fraction of the tumor volume with ≥ 2.7 was 71.9% (black box). As the total tumor volume was 27.9 cm3 (red box), sum of the tumor voxels over the standardized uptake value of the 97.5th percentile of the normal liver tissue voxels of the patient was 20.1 cm3. HCC: Hepatocellular carcinoma; SUV: Standardized uptake value.

**Table 1 Current literature evaluating the role of 18F-fluorodexoyglucose positron emission tomography in staging hepatocellular carcinoma**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **First author** | **Year** | **No. of patients** | **Study design** | **Staging system** | **No. of patient with a change of stage by FDG PET** | **No. of patients with a change of treatment by FDG PET** |
| Yoon *et al*[34] | 2007 | 87 | Not specified | TNM | 4 patients (4.6%),  3 patients TNM IVa to IVb  1 patient TNM III to IVa | Not specified |
| Kawamura *et al*[26] | 2014 | 64 | Retrospective | BCLC | 16 patients (25%),  6 patients BCLC 0 to C  7 patients BCLC A to C  3 patients BCLC B to C | 16 patients (25%) |
| Cho *et al*[35] | 2014 | 457 | Retrospective | BCLC and TNM | 7 patients (1.5%),  6 patients BCLC A to C  1 patient BCLC B to C | 7 patients (1.5%) |

FDG: 18F-fluorodexoyglucose; PET: Positron emission tomography; HCC: Hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer.

**Table 2 Current literature evaluating the prognostic value of 18F-fluorodexoyglucose positron emission tomography in hepatocellular carcinoma patients with surgical resection**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **First author** | **Year** | **No. of patients** | **Study design** | **PET parameter** | **Cut-off values of PET parameter** | **Findings** |
| Hatano *et al*[41] | 2006 | 31 | Retrospective | TLR | 2.0 | TLR showed significant positive association with overall survival |
| Ahn *et al*[47] | 2011 | 93 | Retrospective | SUV, TLR | 4.0, 2.0 | High SUV and TLR were predictors for early recurrence, but showed no statistical significance on multivariate analysis |
| Kitamura *et al*[42] | 2012 | 63 | Retrospective | TLR | 2.0 | TLR was an independent predictor for early recurrence |
| Han *et al*[43] | 2014 | 298 | Retrospective | SUV | 3.5 | SUV was an independent predictor for recurrence-free survival and overall survival |
| Baek *et al*[48] | 2015 | 54 | Retrospective | Tumor-to-muscle ratio | 6.36 | Tumor-to-muscle ratio was associated with recurrence-free survival, but, no statistical significance on multivariate analysis |
| Cho *et al*[44] | 2017 | 56 | Retrospective | SUV | 4.9 | Recurrence rate was higher in patients with high SUV, but, no significant difference of disease-free survival and overall survival according to SUV |
| Hwang *et al*[50] | 2018 | 526 | Retrospective | Visual analysis | - | Combination of ADV score and PET finding can predict risk of early recurrence and survival |
| Kim *et al*[49] | 2018 | 226 HBV-related HCC | Retrospective | Visual analysis | - | Positive PET finding was associated with overall survival, but, not a predisposing factor for disease-free survival in HBV-related HCC patients |
| Lim *et al*[45] | 2018 | 78 | Prospective | Visual analysis | - | Positive PET finding was an independent predictor for early recurrence |
| Yoh *et al*[46] | 2018 | 207 | Retrospective | TLR | 2.0 | Prognostic model incorporating ALBI grade and PET finding can predict the disease-free survival and overall survival |

FDG: 18F-fluorodexoyglucose; PET: Positron emission tomography; HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; TLR: Tumor-to-non-tumor liver uptake ratio; SUV: Standardized uptake value; ADV: Alpha-fetoprotein-Des-gamma-carboxy prothrombin-tumor volume; ALBI: Albumin-bilirubin.

**Table 3 Current literature evaluating the prognostic value of 18F-fluorodexoyglucose positron emission tomography in hepatocellular carcinoma patients with liver transplantation**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **First author** | **Year** | **No. of patients** | **Study design** | **PET parameter** | **Cut-off values of PET parameter** | **Findings** |
| Yang *et al*[51] | 2006 | 38 | Retrospective | Visual analysis | - | Patients with negative PET findings had significantly higher recurrence-free survival than those with positive findings |
| Kornberg *et al*[52] | 2009 | 42 | Retrospective | Visual analysis | - | Patients with positive PET findings had significantly higher recurrence rate with lower recurrence-free survival than those with negative findings |
| Lee *et al*[39] | 2009 | 59 | Retrospective | Tmax/Lmax | 1.15 | Tmax/Lmax was an independent predictor for recurrence-free survival |
| Kornberg *et al*[53] | 2012 | 91 | Retrospective | Visual analysis | - | PET finding was an independent prognostic variable for recurrence-free survival, and positive PET status was the independent predictor of patient dropout from the waiting list of liver transplantation |
| Lee *et al*[54] | 2013 | 191 | Retrospective | Visual analysis | - | Positive PET status was an independent prognostic factor for disease-free survival influencing early recurrence |
| Detry *et al*[55] | 2015 | 27 | Retrospective | Tmax/Lmax | 1.15 | Tmax/Lmax independently predicted recurrence-free survival |
| Hong *et al*[56] | 2016 | 123 | Retrospective | TLR | 1.10 | Combination of serum AFP and PET finding predicted better disease-free survival than using the Milan criteria |
| Hsu *et al*[57] | 2016 | 147 | Retrospective | SUV, TLR | 4.8, 2.0 | Combination of UCSF criteria and PET finding can predict the risk of recurrence |
| Lee *et al*[58] | 2016 | 280 | Retrospective | Visual analysis | - | The criteria combined of FDG PET and total tumor size can predict disease-free survival and overall survival, and showed similar area under the ROC curve of the Milan and UCSF criteria |
| Kornberg *et al*[59] | 2017 | 116 | Retrospective | Visual analysis | - | Combining radiographic criteria with FDG PET finding can predict recurrence-free survival |
| Takada *et al*[60] | 2017 | 182 | Retrospective | Visual analysis | - | PET positive status was an independent risk factor for recurrence-free survival |
| Ye *et al*[61] | 2017 | 103 | Retrospective | Visual analysis | - | Patients beyond the Milan criteria with a negative PET finding had comparable recurrence-free survival in comparison with those within the Milan criteria |

FDG: 18F-fluorodexoyglucose; PET: Positron emission tomography; HCC: Hepatocellular carcinoma; Tmax/Lmax: Maximum FDG uptake of tumor-to-maximum FDG uptake of the normal liver ratio; TLR: Tumor-to-non-tumor liver uptake ratio; SUV: Standardized uptake value; AFP: Alpha-fetoprotein; UCSF: University of California San Francisco; ROC: Receiver operating characteristic.

**Table 4 Current literature evaluating the prognostic value of 18F-fluorodexoyglucose positron emission tomography in hepatocellular carcinoma patients with treatments other than surgical resection and liver transplantation**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **First author** | **Year** | **No. of patients** | **Study design** | **PET parameter** | **Cut-off values of PET parameter** | **Treatment** | **Findings** |
| Song *et al*[64] | 2012 | 83 | Retrospective | TLR | 1.90 | TACE | Patients with low TLR ratios had significantly longer overall survival than those with high ratios, but, no significant difference of time-to-progression was shown between them |
| Song *et al*[65] | 2013 | 58 | Retrospective | TLR | 1.70 | TACE | FDG PET can predict response to TACE and tumor progression |
| Ma *et al*[66] | 2014 | 27 | Retrospective | ΔTSUVmax% | 0.1 | TACE | ΔTSUVmax% can predict response to TACE and overall survival |
| Kim *et al*[67] | 2015 | 77 | Retrospective | TLR | 1.83 | TACE | TLR was an independent predictor of overall survival and tumor progression |
| Kim *et al*[68] | 2011 | 107 | Retrospective | SUV | 6.1 | CCRT | SUV was significantly associated with progression-free survival and overall survival, and patients with high SUV was more likely to have extrahepatic metastasis |
| Huang *et al*[69] | 2013 | 31 | Retrospective | SUV | 3.2 | SABR | SUV was the significant prognostic indicator of disease control rate |
| Rhee *et al*[70] | 2017 | 228 | Retrospective | SUV, TLR | 4.825,2.355 | Radiotherapy | Low FDG uptake group had better treatment response, longer median progression-free and overall survival |
| Kucuk *et al*[71] | 2013 | 19 | Retrospective | Visual analysis | - | Radioembolization | High FDG uptake lesions unexpectedly had better progression-free survival rates |
| Sabet *et al*[72] | 2014 | 33 | Retrospective | Visual analysis | - | Radioembolization | Findings on pre-therapeutic PET and relative changes of FDG uptake on post-therapeutic PET independently predict overall survival |
| Soydal *et al*[73] | 2015 | 28 | Retrospective | Visual analysis, SUV | Not specified | Radioembolization | Age, serum AFP level, and tumor size were significantly associated with survival, but, SUV showed no significant association |
| Abuodeh *et al*[74] | 2016 | 34 | Retrospective | Visual analysis | - | Radioembolization | FDG avidity independently predicts local liver control, distant liver control, and progression-free survival |
| Jreige *et al*[75] | 2017 | 48 | Prospective | SUV, TLR | 5.0,2.0 | Radioembolization | Both SUV and TLR were predictive markers of overall survival |
| Lee *et al*[76] | 2011 | 29 | Retrospective | SUV | 5.0 | Sorafenib | SUV was an independent prognostic factor for overall survival |
| Sung *et al*[40] | 2018 | 35 | Retrospective | TLR | 2.9 | Sorafenib | TLR was significant predictor for progression-free survival and overall survival |

FDG: 18F-fluorodexoyglucose; PET: Positron emission tomography; HCC: Hepatocellular carcinoma; TLR: Tumor-to-non-tumor liver uptake ratio; ΔTSUVmax%: Relative changes of maximum FDG uptake of tumor between pre-therapeutic and post-therapeutic FDG PET scans; SUV: Standardized uptake value; TACE: Transarterial chemoembolization; CCRT: Concurrent chemoradiotherapy; SABR: Streotactic ablative radiotherapy; AFP: Alpha-fetoprotein.